作者
Jesus Garcia-Donas, Emilio Esteban, Luis Javier Leandro-García, Daniel E Castellano, Aranzazu González del Alba, Miguel Angel Climent, José Angel Arranz, Enrique Gallardo, Javier Puente, Joaquim Bellmunt, Begoña Mellado, Esther Martínez, Fernando Moreno, Albert Font, Mercedes Robledo, Cristina Rodríguez-Antona
发表日期
2011/11/1
期刊
The lancet oncology
卷号
12
期号
12
页码范围
1143-1150
出版商
Elsevier
简介
Background
Sunitinib is a tyrosine kinase inhibitor with proven efficacy in renal-cell carcinoma, but some patients do not respond or need dose reductions due to toxicity. Because there are no validated molecular predictors of response or toxicity to sunitinib, we aimed to identify genetic markers predictive of outcome and toxic effects.
Methods
In our observational, prospective study we enrolled previously untreated adults (≥18 years) with clear-cell renal-cell carcinoma at 15 institutions in the Spanish Oncology Genitourinary Group in Spain. Patients received sunitinib according to local practice guidelines. We assessed RECIST response, progression-free survival (PFS), overall survival, and toxicity of sunitinib with 16 key polymorphisms in nine genes: VEGFR2 (rs2305948 and rs1870377), VEGFR3 (rs307826, rs448012, and rs307821), PDGFR-α (rs35597368), VEGF-A (rs2010963, rs699947, and rs1570360), IL8 …
学术搜索中的文章
J Garcia-Donas, E Esteban, LJ Leandro-García… - The lancet oncology, 2011